Castrate Resistant Prostrate Cancer Pipeline Insight
DelveInsight’s, “Castrate Resistant Prostrate Cancer– Pipeline Insights, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Castrate Resistant Prostrate Cancer Understanding
Castrate Resistant Prostrate Cancer: Overview
Castrate-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that is resistant to medical or surgical treatments to lower testosterone, and has spread to other parts of the body. Castrate Resistant Prostrate Cancer is defined by disease progression despite androgen-deprivation (ADT) and may present as one or any combination of a continuous rise in serum levels of prostate-specific antigen (PSA), progression of pre-existing disease, or appearance of new metastases. Castrate-resistant prostate cancer (CRPC) is a form of advanced prostate cancer that is resistant to medical or surgical treatments to lower testosterone, and has spread to other parts of the body.
The symptoms of Castrate Resistant Prostrate Cancer include:
- Urinary frequency and urgency
- Sexual dysfunction
The patient should be screened early and often using the best available tools to identify potential metastasis and optimize treatment outcomes for patients with metastatic disease. Newer options have been developed that offer increased diagnostic accuracy in patients with Castrate Resistant Prostrate Cancer. These include 18F-sodium fluoride PET-CT, MRI, and CT scans.
Immunotherapy with sipuleucel-T should be considered first-line therapy for patients with metastatic Castrate Resistant Prostrate Cancer who are asymptomatic, have low disease burden, and exhibit indolent disease characteristics. Second-generation androgen pathway inhibitors (abiraterone and enzalutamide) should be considered following immunotherapy in the setting of biochemical or clinical progression. Radium Ra 223 dichloride should be considered for patients with bone metastases on the emergence of signs and symptoms of impaired mobility, fatigue, or bone pain. Radium Ra 223 dichloride is an alpha-emitting radionuclide, approved for the treatment with metastatic Castrate Resistant Prostrate Cancer with symptomatic bone metastasis and no known visceral metastasis.
Castrate Resistant Prostrate Cancer Emerging Drugs Chapters
This segment of the Castrate Resistant Prostrate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Castrate Resistant Prostrate Cancer Emerging Drugs
Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.
- Nivolumab: Bristol-Myers Squibb
Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.
Further product details are provided in the report……..
Castrate Resistant Prostrate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Castrate Resistant Prostrate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Castrate Resistant Prostrate Cancer
There are approx. 5+ key companies which are developing the therapies for Castrate Resistant Prostrate Cancer. The companies which have their Castrate Resistant Prostrate Cancer drug candidates in the most advanced stage, i.e. phase III include, Janseen.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Castrate Resistant Prostrate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Castrate Resistant Prostrate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Castrate Resistant Prostrate Cancer drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Castrate Resistant Prostrate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Castrate Resistant Prostrate Cancer
- Novartis in December 2018 announce that it has completed the acquisition of Endocyte, a US biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer.
Castrate Resistant Prostrate Cancer Report Insights
- Castrate Resistant Prostrate Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Castrate Resistant Prostrate Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Castrate Resistant Prostrate Cancer drugs?
- How many Castrate Resistant Prostrate Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Castrate Resistant Prostrate Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Castrate Resistant Prostrate Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Castrate Resistant Prostrate Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bristol-Myers Squibb
- AB Science
- Newsoara Biopharma
- ESSA Pharma